India's Dr Lal PathLabs falls despite strong earnings as lofty valuation weighs
BUZZ-India's Dr Lal PathLabs falls despite strong earnings as lofty valuation weighs ** Dr Lal PathLabs DLPA.NS shares fall 1.3% to 2,003.3 rupees
** Sept-qtr net profit rises over 27% YoY, revenue from operations up about 20%
** "The diagnostics industry continues to benefit from increasing healthcare awareness" - CFO
** Emkay Global ("Buy", TP: 2,300 rupees) says it expects industry tailwinds, along with co's execution prowess to further aid growth acceleration over the remainder of FY27
** Dam Capital ("Buy", TP: 2,334 rupees) says company has weathered rising competition and pricing pressure in recent years while diversifying geographically and steadily improving profitability, strengthening its business model and balance sheet
** Stock trades at forward 12-month PE of 48.29 vs industry median of 41.38 - LSEG-compiled data
** YTD, stock up 36.9%
(Reporting by Abhinav Parmar in Bengaluru)
Recent news on Dr. Lal PathLabs
See all newsIndia's Dr Lal PathLabs falls despite strong earnings as lofty valuation weighs
India's Dr Lal PathLabs posts higher quarterly profit on strong diagnostic test demand
Brief: Lal Pathlabs Sept-Quarter Consol Net Profit 1.92 Billion Rupees
Brief: Lal Pathlabs Says Unit Acquired Remaining 30% Equity Stake In Centrapath Labs Private Limited
India's Dr Lal PathLabs rises as Axis Securities initiates with 'buy'